Outset Medical, Inc. (OM) Form 10-Q — Aug 6, 2026
Outset Medical reported Q2 2026 revenue of $31.6 million, up 1% from $31.4 million a year ago, with a net loss of $18.0 million ($0.97 per share) versus $18.5 million ($1.04) in Q2 2025. Gross margin improved 4.2 points to 42.0% as service and other revenue grew 17%, offsetting a 5% product revenue decline driven by lower consumables. The company held $151.0 million in cash, restricted cash and short-term investments at June 30, 2026 and said it expects this to fund operations for at least 12 months.
Key figures
- Revenue
- 31635000
- Revenue Yoy
- +1% Q2 YoY; -3% six-month YoY
- Total Assets
- 242385000
- Cash Position
- 35005000
- Shares Outstanding
- 18797164
- Six month eps
- -2
- Warrant shares
- 375000
- Gross margin q2 2025
- 37.8%
- Gross margin q2 2026
- 42.0%
- Six month revenue usd
- 59498000
- Q2 product revenue usd
- 21908000
- Q2 service revenue usd
- 9727000
- Warrant exercise price
- 4.838
- Accumulated deficit usd
- 1208338000
- Term loan carrying value usd
- 97647000
- Perceptive additional facility usd
- 25000000
- Remaining performance obligations usd
- 14300000
Price after filing
Close on the filing date to close N calendar days later (from $5.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.